ARTICLE | Company News

CHMP specifies K-Ras status for Erbitux

May 31, 2008 12:33 AM UTC

Merck KGaA (Xetra:MRK) said EMEA's CHMP recommended the use of Erbitux cetuximab to treat patients with EGFR-expressing, K-Ras (KRAS) wild-type metastatic colorectal cancer in combination with chemotherapy and as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan. The recommendation adds first-line use in colorectal cancer to the product's label, but also now specifies K-Ras status for the colorectal cancer indication that was already approved. ...